Advertisement
Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


American Journal of Health-System Pharmacy, Vol. 62, Issue 7, 691-699
Copyright © 2005 by American Society of Health-System Pharmacists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow A correction has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, D. A.
Right arrow Articles by Higginbotham, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, D. A.
Right arrow Articles by Higginbotham, E. J.

Clinical Review

Glaucoma and its treatment: A review

David A. Lee and Eve J. Higginbotham

DAVID A. LEE, M.D., is Pawek-Vallotton Endowed Chair for Biomedical Engineering in Ophthalmology, Professor of Ophthalmology, and Director of the Glaucoma Service, Storm Eye Institute, Medical University of South Carolina, Charleston. EVE J. HIGGINBOTHAM, M.D., is Professor of Ophthalmology and Chair, Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore.

Address correspondence to Dr. Lee at the Storm Eye Institute, Medical University of South Carolina, 167 Ashley Avenue, Room 506, P.O. Box 250676, Charleston, SC 29425 (leedav{at}musc.edu).


Purpose. A review of glaucoma and its treatment is presented.

Summary. Glaucoma is a common eye disease that can cause irreversible blindness if left undiagnosed and untreated. Glaucoma is a leading cause of blindness in the United States and other industrialized countries. In most cases, the symptoms of early-stage glaucoma are minimal or nonexistent. There are several different types of glaucoma, and they have been classically divided into the categories of primary or secondary open-angle or angle-closure glaucoma. Secondary forms of glaucoma are caused by various ocular or systemic diseases. Every available treatment to prevent progressive glaucomatous optic neuropathy has potential adverse effects and involves a certain amount of risk and financial expense. Conventional first-line treatment of glaucoma usually begins with the use of a topical selective or nonselective ß-blocker or a topical prostaglandin analog. Second-line drugs of choice include {alpha}-agonists and topical carbonic anhydrase inhibitors. Parasympathomimetic agents, most commonly pilocarpine, are considered third-line treatment options. For patients who do not respond to antiglaucoma medications, laser trabeculoplasty and incisional surgery are further methods that can be used to lower intraocular pressure. The results of clinical trials have reaffirmed the utility of antiglaucoma medications in slowing the progression of the disease.

Conclusion. Glaucoma is a common eye disease that is usually associated with an elevated intraocular pressure. Treatment options for patients with glaucoma include medications, laser therapy, and incisional surgery. The risks and benefits of each type of treatment must be carefully considered to maximize the treatment’s benefits while minimizing adverse effects.

Index terms: Carbonic anhydrase inhibitors; Costs; Glaucoma; Lasers; Miotics; Optic nerve diseases; Parasympathomimetic agents; Pilocarpine; Prostaglandins; Surgery; Sympatholytic agents; Toxicity

 



This article has been cited by other articles:


Home page
Br J OphthalmolHome page
T Kakaday, A W Hewitt, N H Voelcker, J S J Li, and J E Craig
Advances in telemetric continuous intraocular pressure assessment
Br J Ophthalmol, August 1, 2009; 93(8): 992 - 996.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
J. Jiang, H. S. Gill, D. Ghate, B. E. McCarey, S. R. Patel, H. F. Edelhauser, and M. R. Prausnitz
Coated Microneedles for Drug Delivery to the Eye
Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4038 - 4043.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
C. Baudouin, L. Riancho, J.-M. Warnet, and F. Brignole
In Vitro Studies of Antiglaucomatous Prostaglandin Analogues: Travoprost with and without Benzalkonium Chloride and Preserved Latanoprost
Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4123 - 4128.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
A. Tura, S. Grisanti, K. Petermeier, and S. Henke-Fahle
The Rho-Kinase Inhibitor H-1152P Suppresses the Wound-Healing Activities of Human Tenon's Capsule Fibroblasts In Vitro
Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2152 - 2161.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
L. Zhong, J. Bradley, W. Schubert, E. Ahmed, A. P. Adamis, D. T. Shima, G. S. Robinson, and Y.-S. Ng
Erythropoietin Promotes Survival of Retinal Ganglion Cells in DBA/2J Glaucoma Mice
Invest. Ophthalmol. Vis. Sci., March 1, 2007; 48(3): 1212 - 1218.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
E. Higginbotham
Duplicate publication
Am. J. Health Syst. Pharm., October 1, 2005; 62(19): 1979 - 1979.
[Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
D. A. Lee
Duplicate publication
Am. J. Health Syst. Pharm., October 1, 2005; 62(19): 1979 - 1979.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society of Health-System Pharmacists.
Advertisement